Bifogade filer
250821 SuS Q2 2025 EN
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Surgical Science Sweden AB (publ) via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2025-08-21 07:30:00
Second quarter 2025 (April–June)
- Net sales amounted to SEK 209.2 (212.5) million, a decrease of 2 percent compared with the corresponding period in the preceding year. Delays in order placement meant that the order book for simulators was approximately SEK 30 million larger at the end of the quarter than at the beginning.
- Sales of SEK 22.1 million from Intelligent Ultrasound are included in the figures. For comparable units, sales decreased by 12 percent.
- License revenue amounted to SEK 58.9 (67.1) million and accounted for 28 (32) percent of net sales.
- The gross margin was 65 (68) percent.
- Operating result amounted to SEK -22.4 (33.4) million. Operating result includes negative currency effects in Other operating income and expenses of SEK 24.7 million.
- Net result amounted to SEK -20.1 (28.6) million, corresponding to earnings per share of SEK -0.39 (0.56).
- Cash flow from operating activities amounted to SEK 16.2 (30.0) million. As of June 30, 2025, cash and cash equivalents amounted to SEK 610.2 million (667.1).
First half of 2025 (January–June)
- Net sales amounted to SEK 459.8 (400.7) million, an increase of 15 percent compared with the corresponding period in the preceding year.
- For comparable units, sales increased by 5 percent.
- License revenue amounted to SEK 142.7 (130.3) million and accounted for 31 (33) percent of net sales.
- The gross margin was 67 (67) percent.
- Operating profit amounted to SEK 1.5 (59.4) million. Profit includes SEK 22.6 million in acquisition costs and SEK 3.9 million in restructuring costs, both of which are attributable to the acquisition of Intelligent Ultrasound.
- Net profit amounted to SEK 13.2 (52.4) million, corresponding to earnings per share of SEK 0.26 (1.03).
- Cash flow from operating activities amounted to SEK 11.3 (58.5) million.
- Intelligent Ultrasound, which operates in the field of ultrasound simulation, was acquired in February. The acquisition date was February 18.
Gothenburg, Sweden, August 21, 2025
Surgical Science Sweden AB (publ)
This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/
This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.